vs
Side-by-side financial comparison of Primerica, Inc. (PRI) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Primerica, Inc. is the larger business by last-quarter revenue ($853.7M vs $622.0M, roughly 1.4× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 23.1%, a 11.4% gap on every dollar of revenue. On growth, Primerica, Inc. posted the faster year-over-year revenue change (11.0% vs 4.8%). Over the past eight quarters, Primerica, Inc.'s revenue compounded faster (7.2% CAGR vs 4.6%).
Primerica, Inc. is a multi-level marketing company that provides insurance, investment and financial services to middle-income families in the United States and Canada.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
PRI vs RPRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $853.7M | $622.0M |
| Net Profit | $197.0M | $214.2M |
| Gross Margin | — | — |
| Operating Margin | 28.9% | 62.4% |
| Net Margin | 23.1% | 34.4% |
| Revenue YoY | 11.0% | 4.8% |
| Net Profit YoY | 17.9% | 2.9% |
| EPS (diluted) | $6.11 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $853.7M | $622.0M | ||
| Q3 25 | $839.9M | $609.3M | ||
| Q2 25 | $793.3M | $578.7M | ||
| Q1 25 | $804.8M | $568.2M | ||
| Q4 24 | $768.8M | $593.6M | ||
| Q3 24 | $774.1M | $564.7M | ||
| Q2 24 | $803.4M | $537.3M | ||
| Q1 24 | $742.8M | $568.0M |
| Q4 25 | $197.0M | $214.2M | ||
| Q3 25 | $206.8M | $288.2M | ||
| Q2 25 | $178.3M | $30.2M | ||
| Q1 25 | $169.1M | $238.3M | ||
| Q4 24 | $167.1M | $208.2M | ||
| Q3 24 | $164.4M | $544.0M | ||
| Q2 24 | $1.2M | $102.0M | ||
| Q1 24 | $137.9M | $4.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 98.0% | — | ||
| Q1 24 | 98.2% | — |
| Q4 25 | 28.9% | 62.4% | ||
| Q3 25 | 32.3% | 70.1% | ||
| Q2 25 | 29.6% | 36.3% | ||
| Q1 25 | 27.5% | 94.0% | ||
| Q4 24 | 64.7% | 60.9% | ||
| Q3 24 | 32.9% | — | ||
| Q2 24 | 1.0% | 50.2% | ||
| Q1 24 | 24.1% | -13.0% |
| Q4 25 | 23.1% | 34.4% | ||
| Q3 25 | 24.6% | 47.3% | ||
| Q2 25 | 22.5% | 5.2% | ||
| Q1 25 | 21.0% | 41.9% | ||
| Q4 24 | 21.7% | 35.1% | ||
| Q3 24 | 21.2% | 96.3% | ||
| Q2 24 | 0.1% | 19.0% | ||
| Q1 24 | 18.6% | 0.8% |
| Q4 25 | $6.11 | $0.49 | ||
| Q3 25 | $6.35 | $0.67 | ||
| Q2 25 | $5.40 | $0.07 | ||
| Q1 25 | $5.05 | $0.55 | ||
| Q4 24 | $4.92 | $0.46 | ||
| Q3 24 | $4.83 | $1.21 | ||
| Q2 24 | $0.03 | $0.23 | ||
| Q1 24 | $3.93 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $756.2M | $618.7M |
| Total DebtLower is stronger | — | $9.0B |
| Stockholders' EquityBook value | $2.4B | $9.7B |
| Total Assets | $15.0B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $756.2M | $618.7M | ||
| Q3 25 | $644.9M | $938.9M | ||
| Q2 25 | $621.2M | $631.9M | ||
| Q1 25 | $625.1M | $1.1B | ||
| Q4 24 | $687.8M | $929.0M | ||
| Q3 24 | $550.1M | $950.1M | ||
| Q2 24 | $627.3M | $1.8B | ||
| Q1 24 | $593.4M | $843.0M |
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
| Q4 25 | $2.4B | $9.7B | ||
| Q3 25 | $2.3B | $9.6B | ||
| Q2 25 | $2.3B | $9.5B | ||
| Q1 25 | $2.3B | $9.8B | ||
| Q4 24 | $2.3B | $10.3B | ||
| Q3 24 | $1.9B | $10.3B | ||
| Q2 24 | $2.1B | $9.8B | ||
| Q1 24 | $2.2B | $9.9B |
| Q4 25 | $15.0B | $19.6B | ||
| Q3 25 | $14.8B | $19.3B | ||
| Q2 25 | $14.8B | $18.3B | ||
| Q1 25 | $14.6B | $17.6B | ||
| Q4 24 | $14.6B | $18.2B | ||
| Q3 24 | $14.8B | $18.0B | ||
| Q2 24 | $14.6B | $17.7B | ||
| Q1 24 | $14.9B | $16.1B |
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $338.2M | $827.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.72× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $338.2M | $827.1M | ||
| Q3 25 | $202.9M | $702.6M | ||
| Q2 25 | $162.6M | $364.0M | ||
| Q1 25 | $197.5M | $596.1M | ||
| Q4 24 | $270.6M | $742.5M | ||
| Q3 24 | $207.3M | $703.6M | ||
| Q2 24 | $173.3M | $658.2M | ||
| Q1 24 | $210.9M | $664.6M |
| Q4 25 | 1.72× | 3.86× | ||
| Q3 25 | 0.98× | 2.44× | ||
| Q2 25 | 0.91× | 12.06× | ||
| Q1 25 | 1.17× | 2.50× | ||
| Q4 24 | 1.62× | 3.57× | ||
| Q3 24 | 1.26× | 1.29× | ||
| Q2 24 | 147.98× | 6.45× | ||
| Q1 24 | 1.53× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRI
| Revenues From Sources Other Than Contracts With Customers | $445.9M | 52% |
| Investment And Savings Products Segment Revenues | $340.3M | 40% |
| Other | $56.5M | 7% |
| Segment Revenues From Contracts With Customers | $11.0M | 1% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
